



Medicaid Fee-for-Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective 1/19/2023, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Glumetza** will be **ADDED** to the program

In conformance with State Education Law, which intends patients receive the lower cost drug alternative, brand name drugs included in this program:

- **Do not require ‘Dispense as Written’ (DAW) or ‘Brand Medically Necessary’ on the prescription.**
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of ‘1’; **Pharmacies should submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive a NCPDP reject response of “22” which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this, is DAW code 1 and “*Brand Medically Necessary*” on the prescription.

List of Brand Name Drugs included in this program (updated 12/27/2022)

Advair Diskus	Depakote Sprinkle	Pradaxa
Alphagan P 0.15%	Epipen, Epipen JR	Rapamune solution
Amitiza	Firvang	Renvela tablet
Apriso	Flovent HFA	Restasis
Azopt	Glumetza	Retin-A cream
Bethkis	Kazano	Symbicort
Cellcept suspension	Kitabis Pak	Tegretol suspension
Ciprodex	Lialda	Tegretol XR
Combigan	Nesina	Trileptal suspension
Concerta	Nexavar	Ventolin HFA
Copaxone 20mg	Nuvaring	Zegerid
Daytrana	Pentasa	

Drugs in this program may be subject to prior authorization requirements of other pharmacy programs. This list is subject to change.

